238 related articles for article (PubMed ID: 20564399)
1. Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer.
Yeh JM; Hur C; Kuntz KM; Ezzati M; Goldie SJ
Cancer; 2010 Jun; 116(12):2941-53. PubMed ID: 20564399
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions.
Areia M; Dinis-Ribeiro M; Rocha Gonçalves F
Helicobacter; 2014 Dec; 19(6):425-36. PubMed ID: 25164596
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival.
Yeh JM; Ho W; Hur C
Gastrointest Endosc; 2010 Jul; 72(1):33-43. PubMed ID: 20430384
[TBL] [Abstract][Full Text] [Related]
4. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.
Yeh JM; Hur C; Ward Z; Schrag D; Goldie SJ
Gut; 2016 Apr; 65(4):563-74. PubMed ID: 25779597
[TBL] [Abstract][Full Text] [Related]
5. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
Inadomi JM; Sampliner R; Lagergren J; Lieberman D; Fendrick AM; Vakil N
Ann Intern Med; 2003 Feb; 138(3):176-86. PubMed ID: 12558356
[TBL] [Abstract][Full Text] [Related]
6. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis.
Gupta N; Bansal A; Wani SB; Gaddam S; Rastogi A; Sharma P
Gastrointest Endosc; 2011 Sep; 74(3):610-624.e2. PubMed ID: 21741639
[TBL] [Abstract][Full Text] [Related]
7. Determining the cost-effectiveness of endoscopic surveillance for gastric cancer in patients with precancerous lesions.
Wu JT; Zhou J; Naidoo N; Yang WY; Lin XC; Wang P; Ding JQ; Wu CB; Zhou HJ
Asia Pac J Clin Oncol; 2016 Dec; 12(4):359-368. PubMed ID: 27452189
[TBL] [Abstract][Full Text] [Related]
8. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
[TBL] [Abstract][Full Text] [Related]
9. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
[TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Gastric Cancer Screening According to Race and Ethnicity.
Saumoy M; Schneider Y; Shen N; Kahaleh M; Sharaiha RZ; Shah SC
Gastroenterology; 2018 Sep; 155(3):648-660. PubMed ID: 29778607
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Impact and Cost-Effectiveness of Surveillance of Incidentally Detected Gastric Intestinal Metaplasia: A Microsimulation Analysis.
Thiruvengadam NR; Gupta S; Buller S; Awad I; Gandhi D; Ibarra A; Latorre G; Riquelme A; Kochman ML; Cote G; Shah SC; Saumoy M
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):51-61. PubMed ID: 37302442
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men.
Goldie SJ; Kuntz KM; Weinstein MC; Freedberg KA; Welton ML; Palefsky JM
JAMA; 1999 May; 281(19):1822-9. PubMed ID: 10340370
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus.
Gordon LG; Mayne GC; Hirst NG; Bright T; Whiteman DC; ; Watson DI
Gastrointest Endosc; 2014 Feb; 79(2):242-56.e6. PubMed ID: 24079411
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia.
Dinis-Ribeiro M; da Costa-Pereira A; Lopes C; Moreira-Dias L
J Gastroenterol Hepatol; 2007 Oct; 22(10):1594-604. PubMed ID: 17845687
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
Gerson LB; Groeneveld PW; Triadafilopoulos G
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
[TBL] [Abstract][Full Text] [Related]
16. [Recommended endoscopic surveillance of patients with Barrett's esophagus (BE) is a cost-effective strategy?].
Remes-Troche JM; Ramírez-Arias JF; Gómez-Escudero O; Valdovinos-Andraca F; Vargas-Vorácková F
Rev Gastroenterol Mex; 2006; 71(1):46-54. PubMed ID: 17061478
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis evaluating endoscopic surveillance for gastric cancer for populations with low to intermediate risk.
Zhou HJ; Dan YY; Naidoo N; Li SC; Yeoh KG
PLoS One; 2013; 8(12):e83959. PubMed ID: 24386314
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
19. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies.
Areia M; Carvalho R; Cadime AT; Rocha Gonçalves F; Dinis-Ribeiro M
Helicobacter; 2013 Oct; 18(5):325-37. PubMed ID: 23566268
[TBL] [Abstract][Full Text] [Related]
20. International cost-effectiveness analysis evaluating endoscopic screening for gastric cancer for populations with low and high risk.
Ascherman B; Oh A; Hur C
Gastric Cancer; 2021 Jul; 24(4):878-887. PubMed ID: 33595744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
